Literature DB >> 31237611

1,25-Dihydroxyvitamin D Maintains Brush Border Membrane NaPi2a and Attenuates Phosphaturia in Hyp Mice.

Janaina S Martins1,2, Eva S Liu1,2,3, W Bruce Sneddon4, Peter A Friedman4,5, Marie B Demay1,2.   

Abstract

Phosphate homeostasis is critical for many cellular processes and is tightly regulated. The sodium-dependent phosphate cotransporter, NaPi2a, is the major regulator of urinary phosphate reabsorption in the renal proximal tubule. Its activity is dependent upon its brush border localization that is regulated by fibroblast growth factor 23 (FGF23) and PTH. High levels of FGF23, as are seen in the Hyp mouse model of human X-linked hypophosphatemia, lead to renal phosphate wasting. Long-term treatment of Hyp mice with 1,25-dihydroxyvitamin D (1,25D) or 1,25D analogues has been shown to improve renal phosphate wasting in the setting of increased FGF23 mRNA expression. Studies were undertaken to define the cellular and molecular basis for this apparent FGF23 resistance. 1,25D increased FGF23 protein levels in the cortical bone and circulation of Hyp mice but did not impair FGF23 cleavage. 1,25D attenuated urinary phosphate wasting as early as one hour postadministration, without suppressing FGF23 receptor/coreceptor expression. Although 1,25D treatment induced expression of early growth response 1, an early FGF23 responsive gene required for its phosphaturic effects, it paradoxically enhanced renal phosphate reabsorption and NaPi2a protein expression in renal brush border membranes (BBMs) within one hour. The Na-H+ exchange regulatory factor 1 (NHERF1) is a scaffolding protein thought to anchor NaPi2a to the BBM. Although 1,25D did not alter NHERF1 protein levels acutely, it enhanced NHERF1-NaPi2a interactions in Hyp mice. 1,25D also prevented the decrease in NHERF1/NaPi2a interactions in PTH-treated wild-type mice. Thus, these investigations identify a novel role for 1,25D in the hormonal regulation of renal phosphate handling.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31237611      PMCID: PMC6735734          DOI: 10.1210/en.2019-00186

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  34 in total

1.  Interaction of the type IIa Na/Pi cotransporter with PDZ proteins.

Authors:  S M Gisler; I Stagljar; M Traebert; D Bacic; J Biber; H Murer
Journal:  J Biol Chem       Date:  2000-11-30       Impact factor: 5.157

2.  Renal Na(+)-phosphate cotransporter gene expression in X-linked Hyp and Gy mice.

Authors:  H S Tenenhouse; L Beck
Journal:  Kidney Int       Date:  1996-04       Impact factor: 10.612

3.  1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.

Authors:  Eva S Liu; Janaina S Martins; Adalbert Raimann; Byongsoo Timothy Chae; Daniel J Brooks; Vanda Jorgetti; Mary L Bouxsein; Marie B Demay
Journal:  J Bone Miner Res       Date:  2016-02-02       Impact factor: 6.741

4.  Renal Na/H exchanger NHE-3 and Na-PO4 cotransporter NaPi-2 protein expression in glucocorticoid excess and deficient states.

Authors:  J Loffing; M Lötscher; B Kaissling; J Biber; H Murer; M Seikaly; R J Alpern; M Levi; M Baum; O W Moe
Journal:  J Am Soc Nephrol       Date:  1998-09       Impact factor: 10.121

5.  Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.

Authors:  Emily G Farrow; Lelia J Summers; Susan C Schiavi; James A McCormick; David H Ellison; Kenneth E White
Journal:  J Endocrinol       Date:  2010-07-30       Impact factor: 4.286

6.  A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.

Authors:  Karl L Insogna; Karine Briot; Erik A Imel; Peter Kamenický; Mary D Ruppe; Anthony A Portale; Thomas Weber; Pisit Pitukcheewanont; Hae Il Cheong; Suzanne Jan de Beur; Yasuo Imanishi; Nobuaki Ito; Robin H Lachmann; Hiroyuki Tanaka; Farzana Perwad; Lin Zhang; Chao-Yin Chen; Christina Theodore-Oklota; Matt Mealiffe; Javier San Martin; Thomas O Carpenter
Journal:  J Bone Miner Res       Date:  2018-06-26       Impact factor: 6.741

7.  Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.

Authors:  Ichiro Kaneko; Hiroko Segawa; Kayo Ikuta; Ai Hanazaki; Toru Fujii; Sawako Tatsumi; Shinsuke Kido; Tomoka Hasegawa; Norio Amizuka; Hitoshi Saito; Ken-Ichi Miyamoto
Journal:  Endocrinology       Date:  2018-07-01       Impact factor: 4.736

8.  FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.

Authors:  Jyothsna Gattineni; Carlton Bates; Katherine Twombley; Vangipuram Dwarakanath; Michael L Robinson; Regina Goetz; Moosa Mohammadi; Michel Baum
Journal:  Am J Physiol Renal Physiol       Date:  2009-06-10

9.  Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter.

Authors:  Dominique Prié; Virginie Huart; Naziha Bakouh; Gabrielle Planelles; Olivier Dellis; Bénédicte Gérard; Philippe Hulin; François Benqué-Blanchet; Caroline Silve; Bernard Grandchamp; Gérard Friedlander
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

10.  Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c.

Authors:  Harriet S Tenenhouse; Josée Martel; Claude Gauthier; Hiroko Segawa; Ken-ichi Miyamoto
Journal:  Am J Physiol Renal Physiol       Date:  2003-09-02
View more
  6 in total

1.  Digenic Heterozygous Mutations in SLC34A3 and SLC34A1 Cause Dominant Hypophosphatemic Rickets with Hypercalciuria.

Authors:  Rebecca J Gordon; Dong Li; Daniel Doyle; Joshua Zaritsky; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

2.  Tmem174, a regulator of phosphate transporter prevents hyperphosphatemia.

Authors:  Sumire Sasaki; Yuji Shiozaki; Ai Hanazaki; Megumi Koike; Kazuya Tanifuji; Minori Uga; Kota Kawahara; Ichiro Kaneko; Yasuharu Kawamoto; Pattama Wiriyasermkul; Tomoka Hasegawa; Norio Amizuka; Ken-Ichi Miyamoto; Shushi Nagamori; Yoshikatsu Kanai; Hiroko Segawa
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

3.  Effects of Active Vitamin D or FGF23 Antibody on Hyp Mice Dentoalveolar Tissues.

Authors:  E J Lira Dos Santos; M B Chavez; M H Tan; F F Mohamed; T N Kolli; B L Foster; E S Liu
Journal:  J Dent Res       Date:  2021-04-27       Impact factor: 6.116

Review 4.  Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

Authors:  Michaël R Laurent; Jean De Schepper; Dominique Trouet; Nathalie Godefroid; Emese Boros; Claudine Heinrichs; Bert Bravenboer; Brigitte Velkeniers; Johan Lammens; Pol Harvengt; Etienne Cavalier; Jean-François Kaux; Jacques Lombet; Kathleen De Waele; Charlotte Verroken; Koenraad van Hoeck; Geert R Mortier; Elena Levtchenko; Johan Vande Walle
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

5.  Impaired 1,25 dihydroxyvitamin D3 action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH.

Authors:  Ye Yuan; Supriya Jagga; Janaina S Martins; Rakshya Rana; Paola Divieti Pajevic; Eva S Liu
Journal:  PLoS One       Date:  2021-05-27       Impact factor: 3.752

Review 6.  Cellular and Molecular Alterations Underlying Abnormal Bone Growth in X-Linked Hypophosphatemia.

Authors:  Rocío Fuente; María García-Bengoa; Ángela Fernández-Iglesias; Helena Gil-Peña; Fernando Santos; José Manuel López
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.